An association of Bcl-2 phosphorylation and Bax localization with their functions after hyperthermia and paclitaxel treatment

International Journal of Cancer

Volumn 103, Issue 1, 2003, Pages 53-60

  Salah Eldin, Alaa eldin ^a   Inoue, Shoichi ^a   Tsukamoto, Shigeki ^a   Aoi, Hiromi ^a   Tsuda, Masumi ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Bax; Bcl 2; Hyperthermia; Lung cancer cells; Paclitaxel

Indexed keywords

PACLITAXEL; PROTEIN BAX; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL NUCLEUS; CONTROLLED STUDY; CYTOPLASM; DIMERIZATION; HUMAN; HUMAN CELL; HYPERTHERMIA; LUNG CARCINOMA; LYSOSOME; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL NUCLEUS; CELL SURVIVAL; HUMANS; HYPERTHERMIA, INDUCED; LUNG NEOPLASMS; MICROSCOPY, CONFOCAL; PACLITAXEL; PHOSPHORYLATION; PRECIPITIN TESTS; PROTEIN TRANSPORT; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED;

EID: 0037211320     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.10782     Document Type: Article

References (50)

1. Gregory RE, DeLisa AF. Paclitaxel: A new antineoplastic agent for refractory ovarian cancer. Clin Pharm 1993;12:401-15.
2. Haldar S, Chintapalli J, Croce CM. Taxol induces Bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 1996;56:1253-5.
3. Kumar N. Taxol-induced polymerization of purified tubulin. Mechanism of action. J Biol Chem 1981;256:10435-41.
4. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, ChoChung YS, Longo DL. Involvement of microtubules in the regulation of Bcl-2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 1998;18:3509-17.
5. Othman T, Goto S, Lee JB, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001;62:208-12.
6. Robins HI, Cohen JD, Neville AJ. Whole Body Hyperthermia Biological and Clinical Aspects. Berlin: Springer Verlag, 1992.
7. Cividalli A, Cruciani G, Livdi E, Pasqualetti P, Danesi DT. Hyperthermia enhances the response of paclitaxel and radiation in a mouse adenocarcinoma. Int J Radiat Oncol Biol Phys 1999;44:407-12.
8. Cividalli A, Livdi E, Ceciarelli F, Piscitelli M, Pasqualetti P, Cruciani G, Danesi DT. Hyperthermia and paclitaxel-epirubicin chemotherapy: Enhanced cytotoxic effect in a murine mammary adenocarcinoma. Int J Hyperthermia 2000;16:61-71.
9. van Bree C, Savonije JH, Franken NA, Haveman J, Bakker PJ. The effect of p53-function on the sensitivity to paclitaxel with or without hyperthermia in human colorectal carcinoma cells. Int J Oncol 2000; 16:739-44.
10. Leal BZ, Meltz ML, Mohan N, Kuhn J, Prihoda TJ, Herman TS. Interaction of hyperthermia with Taxol in human MCF-7 breast adenocarcinoma cells. Int J Hyperthermia 1999;15:225-36.
11. Oltvai Z, Milliman C, Korsmeyer S. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993;74:609-19.
12. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ, Shore GC. Regulated targeting of Bax to mitochondria. J Cell Biol 1998;143:207-15.
13. Gross A, Jockel J, Wei MC, Korsmeyer SJ. Enforced dimerization of Bax results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998;17:3878-85.
14. Hsu YT, Wolter KG, Youle RJ. Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 1997;94:3668-72.
15. Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ. Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 1997;139:1281-92.
16. Wang M, Aime-Sempe C, Sato T, Reed JC. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. J Biol Chem 1995;270:11962-9.
17. Haldar S, Basu A, Croce CM. Bcl-2 is the guardian of microtubule integrity. Cancer Res 1997;57:229-33.
18. Hickman JA. Apoptosis induced by anticancer drugs. Cancer Metastasis Rev 1992; 11:121-39.
19. Pietenpol JA, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B. Paradoxical inhibition of solid tumor cell growth by Bcl-2. Cancer Res 1994;54:3714-7.
20. Rodi DJ, Janes RW, Sanganee HJ, Holton RA, Wallace BA, Makowski L. Screening of a library of phage-displayed peptides identifies human Bcl-2 as a taxol-binding protein. J Mol Biol 1999;285:197-203.
21. Blagosklonny MV, Schulte TW, Nguyen P, Mimnaugh EG, Trepel J, Neckers L. Taxol induction of p21WAF1 and p53 requires c-raf-1. Cancer Res 1995;55:4623-6.
22. Blagosklonny MV, Schulte TW, Nguyen P, Trepel J, Neckers LM. Taxol-induced apoptosis and phosphorylation of Bcl-2 protein involves c-Raf-I and represents a novel c-Raf-1 signal transduction pathway. Cancer Res 1996;56:1851-4.
23. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DJ, Higgs PI, Neckers L, Fojo T. Raf-1/Bcl-2 phosphorylation: A step from microtubule damage to cell death. Cancer Res 1997;57:130-5.
24. Haldar S, Jena N, Croce CM. Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 1995;92:4507-11.
25. Haldar S, Basu A, Croce CM. Serine-70 is one of the critical sites for drug-induced Bcl-2 phosphorylation in cancer cells. Cancer Res 1998; 58:1609-15.
26. Ibrado AM, Liu L, Bhalla K. Bcl-xL overexpression inhibits progression of molecular events leading to paclitaxel-induced apoptosis of human acute myeloid leukemia HL-60 cells. Cancer Res 1997;57:1109-15.
27. May WS, Tyler PG, Ito T, Armstrong DK, Qatsha KA, Davidson NE. Interleukin-3 and bryostatin-1 mediate hyperphosphorylation of Bcl-2 alpha in association with suppression of apoptosis. J Biol Chem 1994;269:26865-70.
28. Srivastava RK, Sasaki CY, Hardwick JM, Longo DL. Bcl-2-mediated drug resistance: Inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription. J Exp Med 1999;190:253-65.
29. Ouyang H, Furukawa T, Abe T, Kato Y, Horii A. The Bax gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin Cancer Res 1998;4:1071-4.
30. Sakao Y, Noro M, Sekine S, Nozue M, Hirohashi S, Itoh T, Noguchi M. Microsatellite instability and frameshift mutations in the Bax gene in hereditary nonpolyposis colorectal carcinoma. Jpn J Cancer Res 1998;89:1020-7.
31. Salah-eldin A, Inoue S, Tsuda M, Matsuura A. Abnormal intracellular localization of Bax with a normal membrane anchor domain in human lung cancer cell lines. Jpn J Cancer Res 2000;91:1269-77.
32. Nechushtan A, Smith CL, Hsu YT, Youle RJ. Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999;18:2330-41.
33. Priault M, Camougrand N, Chaudhuri B, Manon S. Role of the C-terminal domain of Bax and Bcl-XL in their localization and function in yeast cells. FEBS Lett 1999;443:225-8.
34. Lopez E, Pozas E, Rivera R, Ferrer I. Bcl-2, Bax and Bcl-x expression following kainic acid administration at convulsant doses in the rat. Neuroscience 1999;91:1461-70.
35. Mandal M, Adam L, Mendelsohn J, Kumar R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene 1998:17:999-1007.
36. Nishita M, Inoue S, Tsuda M, Tateda C, Miyashita T. Nuclear translocation and increased expression of Bax and disturbance in cell cycle progression without prominent apoptosis induced by hyperthermia. Exp Cell Res 1998;244:357-66.
37. Thielmann HW, Popanda O, Staab HJ. Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan. J Cancer Res Clin Oncol 1999;125:193-208.
38. Wang ZH, Ding MX, Chew-Cheng SB, Yun JP, Chew EC. Bcl-2 and Bax proteins are nuclear matrix associated proteins. Anticancer Res 1999;19:5445-9.
39. Arends J. Effects of a combined thermochemotherapy on markers of apoptosis, differentiation and adhesion in the human mammary carcinoma MX-1. A light microscopic and immunohistochemical study. Anat Anz 2000;182:339-47.
40. Inoue S, Takaoka K, Endo T, Mizuno S, Ogawa Y, Yoshida M, Ohnuma T. In vitro confirmation of newly established lung cancer cell lines using flow cytometry and multicellular tumor spheroids. Lung Cancer 1997;17:85-101.
41. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi CA. Rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 1991;139:271-9.
42. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol 1994;145:1323-36.
43. Shitashige M, Toi M, Yano T, Shibata M, Matsuo Y, Shibasaki F. Dissociation of Bax from a Bcl-2/Bax heterodimer triggered by phosphorylation of serine 70 of Bcl-2. J Biochem 2001;130:741-8.
44. Yamamoto K, Ichijo H, Korsmeyer SJ. Bcl-2 is phosphorylated and inactivated by an ASK1/Jun N-terminal protein kinase pathway normally activated at G2/M. Mol Cell Biol 1999;19:8469-78.
45. Fun M, Du L, Stone AA, Gilbert KM, Chambers TC. Modulation of mitogen-activated protein kinases and phosphorylation of Bcl-2 by vinblastine represent persistent forms of normal fluctuations at G2M. Cancer Res 2000;60:6403-7.
46. Blagosklonny MV. Unwinding the loop of Bcl-2 phosphorylation. Leukemia 2001;15:869-74.
47. Blagosklonny MV, Fojo T. Molecular effects of paclitaxel: Myths and reality (a critical review). Int J Cancer 1999;83:151-6.
48. Giannakakou P, Robey R, Fojo T, Blagosklonny MV. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: Molecular determinants of paclitaxel-induced cytotoxicity. Oncogene 2001;28:3806-13.
49. Reed JC. Cytochrome c: Can't live with it - Can't live without it. Cell 1997;91:559-62.
50. Xiang J, Chao DT, Korsmeyer SJ. Bax-induced cell death may not require interleukin 1 beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996;93:14559-63.